For instance, considering that FTO upregulation of MERTK and BCL2 contributes to CML TKI resistance, a combination of catalytic FTO inhibitors with MERTK-targeting monoclonal antibodies or selective BCL2 inhibitors like venetoclax could be explored. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.